[The significance of postprandial glycemia].
Both acute and chronic hyperglycemia cause tissue lesions which ultimately lead to micro- and macrovascular diabetic complications. The newly developed insulin secretagogues and quick-acting insulin analogues are pharmacological options to reduce the amplitude of glucose fluctuations, thereby reducing acute glucose toxicity. There is hope that new pathophysiologically based therapeutic options will improve glucose control of type 2 diabetes and that physicians can be convinced to change their frequently expressed opinion that rising glucose levels represent the natural course of the disease. The Diabetes Control and Complications Trial has clearly shown that intensive insulin therapy is effective in treating complete insulin deficiency in type 1 diabetes over many years, achieving a stable HbA1c and thereby preventing diabetic complications [1].
Lehmann
R
R
Abteilung für Endokrinologie und Diabetologie Universitätsspital Zürich Rämistrasse 10 8091 Zürich.
D001786:Blood Glucose / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000175:diagnosis*; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D019518:Postprandial Period / Q000502:physiology*; D012307:Risk Factors
D001786:Blood Glucose; D006442:Glycated Hemoglobin